Business

Moderna shares soar 135% in a day after cancer vaccine succeeds in late-stage trial

By Sohail Khan 19 August 2026, 7:56 pm

Benchmarks
Nifty24,078.30-76.61

FEATURED FUNDS★★★★★

Motilal Oswal Midcap Fund Direct-Growth

5Y Return
23.26 %

Invest Now

Enter search text:

Business News›Markets›US Stocks›Wall St Guide›Moderna shares soar 135% in a day after cancer vaccine succeeds in late-stage trial

Read Today's Paper

Synopsis

Moderna shares surged after its personalized mRNA cancer vaccine trial showed positive results. The treatment, combined with Keytruda, reduced melanoma recurrence and spread significantly. This marks the first successful late-stage trial for an mRNA cancer vaccine. The findings offer hope for future growth beyond COVID-19 vaccines. Discussions with regulators are expected within the next few months.

Moderna shares soar 135% in a day after cancer vaccine succeeds in late-stage trial

Moderna shares rallied about 135% to $148.02 on Wednesday after its personalised mRNA cancer vaccine, developed with Merck, reduced the risk of melanoma recurrence and spread when combined with Keytruda in a late-stage trial, Reuters reported.

The stock rose as high as $149.63 after closing the previous session at $62.96.

Interim results from the ongoing study showed that the treatment, Intismeran, met its primary goal of reducing cancer recurrence and its secondary objective of preventing tumours from spreading to other parts of the body, compared with Keytruda alone, Reuters reported.

The results mark the first successful late-stage trial of an mRNA cancer vaccine. It is also the first study to show that adding another treatment to Keytruda worked better than Keytruda alone in patients whose melanoma had been surgically removed.

Merck shares gained 11% to $150/14 in early trading.

The findings could help ease investor concerns about the companies’ long-term growth prospects. Moderna has been seeking growth beyond its COVID-19 vaccine, while Merck is preparing for Keytruda, its blockbuster cancer therapy, to lose patent protection later this decade, according to the Reuters report.

William Blair analyst Myles Minter said the interim results put both companies in a strong position to seek regulatory approval. He added that the findings were also encouraging for ongoing studies of the vaccine in other types of cancer.

Merck research and development chief Dean Li told CNBC that the companies expected to begin discussions with regulators within the next few months.

Barclays analysts estimated last month that the therapy could generate about $3 billion in melanoma-related sales by 2035.

Pricing remains undecided

JP Morgan analysts told Reuters the launch of Intismeran as an adjuvant treatment for melanoma would be crucial to Moderna’s return to profitability.

The therapy combines Merck’s Keytruda with a made-to-order Moderna mRNA vaccine designed using an analysis of mutations found in each patient’s tumour.

The trial enrolled 1,137 high-risk patients with stage IIB to stage IV melanoma that had been surgically removed. Participants were randomly assigned to receive up to nine doses of the personalised vaccine alongside Keytruda, or Keytruda alone, for about one year.

The companies said no new safety concerns had emerged during the trial.

In January, they released five-year results from a mid-stage study showing that the combination reduced the risk of cancer recurrence or death by 49%.

Moderna CEO Stéphane Bancel said the companies had not yet decided on a price for the treatment because the latest data had become available only a few days earlier.

Unlike some personalised cell therapies, the treatment does not use a patient’s own cells, which could allow the manufacturing process to be scaled up and costs to be reduced, Bancel said.

Melanoma is the deadliest form of skin cancer. More than 1.5 million people in the United States were living with the disease in 2023, according to the National Cancer Institute

(Disclaimer: This article is based on inputs from agencies. These do not represent the views of The )

Add as a Reliable and Trusted News Source
Add Now!

(You can now subscribe to our ETMarkets WhatsApp channel)

(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .)

Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price

…moreless

(You can now subscribe to our ETMarkets WhatsApp channel)

Read More News on
ModernaModerna stockModerna cancer vaccineModerna share priceWhy Moderna stock rosemRNA cancer vaccineModerna Merck

Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price

…moreless

Enter search text:

BrowseCompanies:
ABCDEFGHIJKLMNOPQRSTUVWXYZ
123456789

Continue reading with one of these options:
Limited Access
Free
Login to get access to some exclusive stories

& personalised newsletters
Login Now

Unlimited Access
Starting @ Rs120/month
Get access to exclusive stories, expert opinions &

in-depth stock reports
Subscribe Now

Unlock Access to All Exclusives with ETPrime FREE TRIAL

15 Days Free: Unlock All ETPrime Exclusives, Market Tools & ePapers

Trial offer expiring in00 : 05 : 00

I'd rather pay ₹2599 now

Uh-oh! This is an exclusive story available for selected readers only.

Worry not. You’re just a step away.

Prime Account Detected!

It seems like you're already an ETPrime member with

Log out of your current logged-in account and log in again using your ET Prime credentials to enjoy all member benefits.

Unlock ETPrime's Exclusive Stories Today!

Subscribe to gain powerful insights on business, stock market and industry trends.

Big Price Drop! Flat 40% Off

Student Only Offer

Already a Member? Sign In now

Already a Member? Sign In now
Already a Member? Sign In now

Offer Exclusively For You

Save up to Rs. 700/-

ON ET PRIME MEMBERSHIP

Avail Offer

Offer Exclusively For You

Get 1 Year Free

With 1 and 2-Year ET prime membership

Avail Offer

Offer Exclusively For You

Get 1 Year Free

With 1 and 2-Year ET prime membership

Avail Offer

Offer Exclusively For You

Get Flat 40% Off

Then ₹ 1749 for 1 year

Avail Offer

Offer Exclusively For You

ET Prime at ₹ 49 for 1 month

Then ₹ 1749 for 1 year

Avail Offer

Special Offer

Get flat 40% off on ETPrime

Avail Offer
Avail Offer

Claim NowAlready a Member? Sign In now

Need Assistance?

Connect with an ETPrime expert for personalized support and guidance

+91 9484700004

' + h3 + '

' + h4 + '

' + listing + '

What’s Included with

ETPrime Membership

1Exclusive Insights That Matter

Uncover the truth with our investigative stories

Make strategic moves using the real-world case studies

Read industry-specific stories to identify emerging trends

Spot opportunities with in-depth insights that matter

Trump temper on H-1B visas is forcing Indians to do these things to stay put in US

What Adani’s US indictment means for India Inc’s overseas fundraising
Why veterans like Reliance, L&T are on acquisition spree? Aswath Damodaran has an answer.

Will China’s dollar bond sale in Saudi Arabia trump the US in financial world?
Huawei launches its own OS to compete with Google and Apple. But can it win beyond China?

The problem with lab grown diamonds
Why a falling rupee is a better option for the economy

A list of top 20 momentum stocks that have delivered massive returns in one year